Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
The Slovak Spectator on MSN1h
Slovakia’s gets a new digital guide for hiker's adventure seekersA new platform for hikers and explorers in Slovakia Slovakia has a new social network, one focused on hiking: Turistník.sk. Its developers say it is designed to inspire people to discover new places.
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...
Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...
Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...
Pattinson has racked up an impressive filmography full of fascinating directors who have allowed him to evolve into a ...
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback